|
1
|
Yeh CM, Su SC, Lin CW, Yang WE, Chien MH,
Reiter RJ and Yang SF: Melatonin as a potential inhibitory agent in
head and neck cancer. Oncotarget. 8:90545–90556. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stanciu AE, Zamfir-Chiru-Anton A, Stanciu
MM, Popescu CR, Gheorghe DC and Nitipir C: Serum matrix
metalloproteinase-2 in head and neck squamous cell carcinoma is
associated with tumor differentiation. Rom Biotech Lett.
22:12419–12426. 2017.
|
|
3
|
Koziorowski J, Stanciu AE, Gomez-Vallejo V
and Llop J: Radiolabeled nanoparticles for cancer diagnosis and
therapy. Anticancer Agents Med Chem. 17:333–354. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gialeli C, Theocharis AD and Karamanos NK:
Roles of matrix metalloproteinases in cancer progression and their
pharmacological targeting. FEBS J. 278:16–27. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stanciu AE, Vatasescu RG, Stanciu MM,
Serdarevic N and Dorobantu M: The role of pro-fibrotic biomarkers
in paroxysmal and persistent atrial fibrillation. Cytokine.
103:63–68. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stanciu AE, Zamfir-Chiru-Anton A, Stanciu
MM, Popescu CR and Gheorghe DC: Imbalance between matrix
metalloproteinases and tissue inhibitors of metalloproteinases
promotes invasion and metastasis of head and neck squamous cell
carcinoma. Clin Lab. 63:1613–1620. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Patel BP, Shah SV, Shukla SN, Shah PM and
Patel PS: Clinical significance of MMP-2 and MMP-9 in patients with
oral cancer. Head Neck. 29:564–572. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stanciu AE, Zamfir-Chiru-Anton A, Stanciu
MM, Popescu CR and Gheorghe DC: Serum level of matrix
metalloproteinase-9 in patients with head and neck squamous cell
carcinoma. Clin Lab. 62:1569–1574. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Burduk PK, Sawicki P, Szylberg L, Bodnar M
and Marszalek A: Expression of matrix metalloproteinase-2/9 and
tissue inhibitor of metalloproteinase-1/2 as predictive factors in
oropharyngeal squamous cell carcinoma. Iran J Otorhinolaryngol.
31:153–161. 2019.PubMed/NCBI
|
|
10
|
Hanedan Uslu G, Canyilmaz E, Serdar L and
Ersöz S: Protective effects of genistein and melatonin on mouse
liver injury induced by whole-body ionising radiation. Mol Clin
Oncol. 10:261–266. 2019.PubMed/NCBI
|
|
11
|
Laurent V, Sengupta A, Sánchez-Bretaño A,
Hicks D and Tosini G: Melatonin signaling affects the timing in the
daily rhythm of phagocytic activity by the retinal pigment
epithelium. Exp Eye Res. 165:90–95. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Siah KT, Wong RK and Ho KY: Melatonin for
the treatment of irritable bowel syndrome. World J Gastroenterol.
20:2492–2498. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Slominski A, Fischer TW, Zmijewski MA,
Wortsman J, Semak I, Zbytek B, Slominski RM and Tobin DJ: On the
role of melatonin in skin physiology and pathology. Endocrine.
27:137–148. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Conti A, Conconi S, Hertens E,
Skwarlo-Sonta K, Markowska M and Maestroni JM: Evidence for
melatonin synthesis in mouse and human bone marrow cells. J Pineal
Res. 28:193–202. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Isola M and Lilliu MA: Melatonin
localization in human salivary glands. J Oral Pathol Med.
45:510–515. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang WS, Deng Q, Fan WY, Wang WY and Wang
X: Light exposure at night, sleep duration, melatonin, and breast
cancer: A dose-response analysis of observational studies. Eur J
Cancer Prev. 23:269–276. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tai SY, Huang SP, Bao BY and Wu MT:
Urinary melatonin-sulfate/cortisol ratio and the presence of
prostate cancer: A case control study. Sci Rep. 6:296062016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao M, Wan JY, Zeng K, Tong M, Lee AC,
Ding JX and Chen Q: The reduction in circulating melatonin level
may contribute to the pathogenesis of ovarian cancer: A
retrospective study. J Cancer. 7:831–836. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chok KC, Ng CH, Koh RY, Ng KY and Chye SM:
The potential therapeutic actions of melatonin in colorectal
cancer. Horm Mol Biol Clin Investig. May 29–2019.(Epub ahead of
print). doi: 10.1515/hmbci-2019-0001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu H, Wu B, Ma G, Zheng D, Song R, Huang
E, Mao M and Lu B: Melatonin represses oral squamous cell carcinoma
metastasis by inhibiting tumor-associated neutrophils. Am J Transl
Res. 9:5361–5374. 2017.PubMed/NCBI
|
|
21
|
Yeh CM, Lin CW, Yang JS, Yang WE, Su SC
and Yang SF: Melatonin inhibits TPA-induced oral cancer cell
migration by suppressing matrix metalloproteinase-9 activation
through the histone acetylation. Oncotarget. 7:21952–21967. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ho HY, Lin CW, Chien MH, Reiter RJ, Su SC,
Hsieh YH and Yang SF: Melatonin suppresses TPA-induced metastasis
by downregulating matrix metalloproteinase-9 expression through
JNK/SP-1 signaling in nasopharyngeal carcinoma. J Pineal Res.
61:479–492. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang CY, Lin CK, Tsao CH, Hsieh CC, Lin
GJ, Ma KH, Shieh YS, Sytwu HK and Chen YW: Melatonin exerts
anti-oral cancer effect via suppressing LSD1 in patient-derived
tumor xenograft models. Oncotarget. 8:33756–33769. 2017.PubMed/NCBI
|
|
24
|
Mannello F, Jung K, Tonti GA and
Canestrari F: Heparin affects matrix metalloproteinases and tissue
inhibitors of metalloproteinases circulating in peripheral blood.
Clin Biochem. 41:1466–1473. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Amin MB, Edge S, Greene F, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC Cancer Staging Manual, eighth edition
(2017) published by Springer Science and Business Media LLC
(springer.com). AJCC Cancer Staging Manual. 8th. Springer; New
York, NY: 2017, View Article : Google Scholar
|
|
26
|
Lydiatt WM, Patel SG, O'Sullivan B,
Brandwein MS, Ridge JA, Migliacci JC, Loomis AM and Shah JP: Head
and Neck cancers-major changes in the American Joint Committee on
cancer eighth edition cancer staging manual. CA Cancer J Clin.
67:122–137. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
El-Naggar AK, Chan JKC, Grandis JR, Takata
T and Slootweg PJ: WHO Classification of Head and Neck Tumours. WHO
Classification of Tumours. 4th. 9. WHO Press; Geneva: 2017
|
|
28
|
Kennaway DJ: A critical review of
melatonin assays: Past and present. J Pineal Res. 67:e125722019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Karkela J, Vakkuri O, Kaukinen S, Huang WQ
and Pasanen M: The influence of anaesthesia and surgery on the
circadian rhythm of melatonin. Acta Anaesthesiol Scand. 46:30–36.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vacas S, Kurien P and Maze M: Sleep and
Anesthesia Common mechanisms of action. Sleep Med Clin. 8:1–9.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Norouzi A, Fateh S, Modir H, Kamali A and
Akrami L: Premedication effect of melatonin on propofol induction
dose for anesthesia, anxiety, orientation and sedation after
abdominal surgery: A double-blinded randomized trial. Med Gas Res.
9:62–67. 2019.PubMed/NCBI
|
|
32
|
Wang G, Liu J, Gao J and Zheng X:
Comparison of the effects of sevoflurane and propofol anesthesia on
pulmonary function, MMP-9 and postoperative cognition in patients
receiving lung cancer resection. Oncol Lett. 17:3399–3405.
2019.PubMed/NCBI
|
|
33
|
Vasaturo F, Solai F, Malacrino C, Nardo T,
Vincenzi B, Modesti M and Scarpa S: Plasma levels of matrix
metalloproteinases 2 and 9 correlate with histological grade in
breast cancer patients. Oncol Lett. 5:316–320. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin FY, Lin CW, Yang SF, Lee WJ, Lin YW,
Lee LM, Chang JL, Weng WC, Lin CH and Chien MH: Interactions
between environmental factors and melatonin receptor type 1A
polymorphism in relation to oral cancer susceptibility and
clinicopathologic development. PLoS One. 10:e01216772015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lin FY, Hsieh YH, Yang SF, Chen CT, Tang
CH, Chou MY, Chuang YT, Lin CW and Chen MK: Resveratrol suppresses
TPA-induced matrix metalloproteinase-9 expression through the
inhibition of MAPK pathways in oral cancer cells. J Oral Pathol
Med. 44:699–706. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lin YW, Lee LM, Lee WJ, Chu CY, Tan P,
Yang YC, Chen WY, Yang SF, Hsiao M and Chien MH: Melatonin inhibits
MMP-9 transactivation and renal cell carcinoma metastasis by
suppressing Akt-MAPKs pathway and NF-κB DNA-binding activity. J
Pineal Res. 60:277–290. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rudra DS, Pal U, Maiti NC, Reiter RJ and
Swarnakar S: Melatonin inhibits matrix metalloproteinase-9 activity
by binding to its active site. J Pineal Res. 54:398–405. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Stanciu AE, Zamfir-Chiru-Anton A, Stanciu
MM, Pantea Stoian A, Jinga V, Nitipir C, Bucur A, Pituru TS, Arsene
AL, Dragoi CM, et al: Clinical significance of serum melatonin in
predicting the severity of oral squamous cell carcinoma. Oncol
Lett. 19:1537–1543. 2019.PubMed/NCBI
|
|
39
|
Nakamura E, Kozaki K, Tsuda H, Suzuki E,
Pimkhaokham A, Yamamoto G, Irie T, Tachikawa T, Amagasa T, Inazawa
J and Imoto I: Frequent silencing of a putative tumor suppressor
gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell
carcinoma. Cancer Sci. 99:1390–400. 2008. View Article : Google Scholar : PubMed/NCBI
|
